LASSBio-1920 showed high activity against all tumor cell lines with IC50 values ranging from 0.06 to 1.68 μM, being more active than its precursor LASSBio-1586 and other inhibitors of receptor tyrosine kinases, such as pelitinib and sunitinib. This evidence concerns the gene NTRK1 and neoplasm.